BIOLASE and P&G
This article was originally published in The Tan Sheet
BIOLASE announces Jan. 25 it has signed a definitive licensing agreement with Procter & Gamble to provide P&G with intellectual property for use in consumer products. P&G paid the Irvine, Calif.-based firm an upfront fee of $3 mil. The definitive licensing agreement says P&G will pay BIOLASE royalties based on product sales, milestone payments and quarterly payments of $250,000 until the first product is launched, the company says. BIOLASE's LaserSmile system uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.